The potential Corona vaccine developed by the American pharmaceutical company has succeeded Pfizer And biotechnology company BioNTech In the occurrence of a “robust” immune response in healthy adults between the ages of 18 and 55, according to an interim report of an early clinical trial, published in the journal Nature today, Wednesday.
According to a newspaper report timesnownews The researchers note that BNT162b1 It is a vaccine from RNA It evokes an immune response by mimicking a molecule mRNA Which the new coronavirus uses to build infectious proteins.
According to the study, the candidate vaccine is given by intramuscular injection, and it enables human cells to produce proteins that are part of the corona receptor binding domain, against which the immune system is trained against to produce antibodies..
The researchers said that such vaccines are generally considered safe and have facilitated the rapid development of vaccines against Corona, as it is one of many candidate RNA vaccines that are being studied in parallel for selection to progress to experiment with their safety and effectiveness..
In Phase 1/2 of the trial, scientists evaluated the safety, side effects, and safe dose of a vaccine candidate in 45 healthy adults (23 men and 22 non-pregnant women) ages 18 to 55 years..
The study indicated that participants were randomly assigned to receive 10 micrograms (g), 30 gm, or 100 gm BNT162b1 Or a placebo, and the scientists said that participants in the two groups of 10g and 30g also received a second dose on Day 21
Based on the study, the researchers said that BNT162b1 It was generally well tolerated, although some participants experienced mild to moderate side effects, which increased with dose level, in the 7 days following vaccination, including pain at the injection site, fatigue, headache, and fever. And sleep disturbance.
They explained that the vaccine evoked a “strong immune response” in the participants, which increased with the dose level, and with a second dose according to the study, the antibodies against corona were present 21 days after a single vaccination at all dose levels, and there was a significant increase in antibodies to SARS-CoV-2 Seven days later, the second 10- g or 30.
He observed that the immune response was much stronger in the 30g group than in the 10g group.However, the scientists said that there were no noticeable differences in the immune response between the 30 and 100g groups after a single dose, and since the participants who received the 100g dose also experienced greater side effects, they did not receive a second dose. .
They said that the participants’ neutralizing antibody levels were 1.9 to 4.6 times higher than those in patients recovering from SARS infection..
Although this comparison provides a criterion for assessing the immune response resulting from the vaccine and the ability of the vaccine to provide protection, researchers believe that phase III trials are necessary to determine efficacy. BNT162b1.
The study also enrolls adults between the ages of 65 and 85, they said, adding that the later stages will prioritize registering more diverse groups.